Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
ECYT's Cash-to-Debt is ranked higher than
81% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ECYT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ECYT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.96
ECYT's Equity-to-Asset is ranked higher than
95% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ECYT: 0.96 )
Ranked among companies with meaningful Equity-to-Asset only.
ECYT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45  Med: 0.95 Max: 0.97
Current: 0.96
0.45
0.97
Interest Coverage No Debt
ECYT's Interest Coverage is ranked higher than
74% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ECYT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ECYT' s Interest Coverage Range Over the Past 10 Years
Min: 5027  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 8.89
Beneish M-Score: -3.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -64038.89
ECYT's Operating Margin % is ranked lower than
99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ECYT: -64038.89 )
Ranked among companies with meaningful Operating Margin % only.
ECYT' s Operating Margin % Range Over the Past 10 Years
Min: -64038.89  Med: -2023.2 Max: 7.15
Current: -64038.89
-64038.89
7.15
Net Margin % -62811.11
ECYT's Net Margin % is ranked lower than
99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ECYT: -62811.11 )
Ranked among companies with meaningful Net Margin % only.
ECYT' s Net Margin % Range Over the Past 10 Years
Min: -62811.11  Med: -2132.74 Max: 7.76
Current: -62811.11
-62811.11
7.76
ROE % -31.06
ECYT's ROE % is ranked higher than
55% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ECYT: -31.06 )
Ranked among companies with meaningful ROE % only.
ECYT' s ROE % Range Over the Past 10 Years
Min: -492.46  Med: -20.57 Max: 3.72
Current: -31.06
-492.46
3.72
ROA % -29.92
ECYT's ROA % is ranked higher than
51% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ECYT: -29.92 )
Ranked among companies with meaningful ROA % only.
ECYT' s ROA % Range Over the Past 10 Years
Min: -91.6  Med: -27.27 Max: 2.91
Current: -29.92
-91.6
2.91
ROC (Joel Greenblatt) % -1382.47
ECYT's ROC (Joel Greenblatt) % is ranked lower than
65% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ECYT: -1382.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ECYT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3911.11  Med: -1354.54 Max: 128.73
Current: -1382.47
-3911.11
128.73
3-Year Revenue Growth Rate -89.60
ECYT's 3-Year Revenue Growth Rate is ranked lower than
92% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ECYT: -89.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ECYT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -88.45 Max: 522.1
Current: -89.6
0
522.1
3-Year EBITDA Growth Rate 28.40
ECYT's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ECYT: 28.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ECYT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -70.1 Max: 29.1
Current: 28.4
0
29.1
3-Year EPS without NRI Growth Rate 27.70
ECYT's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ECYT: 27.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ECYT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -70.5 Max: 27.7
Current: 27.7
0
27.7
GuruFocus has detected 3 Warning Signs with Endocyte Inc $ECYT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ECYT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ECYT Guru Trades in Q2 2016

Jim Simons Sold Out
» More
Q3 2016

ECYT Guru Trades in Q3 2016

Jim Simons 189,000 sh (New)
» More
Q4 2016

ECYT Guru Trades in Q4 2016

Jim Simons 50,100 sh (-73.49%)
» More
Q1 2017

ECYT Guru Trades in Q1 2017

Jim Simons 192,561 sh (+284.35%)
» More
» Details

Insider Trades

Latest Guru Trades with ECYT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VVUS, NAS:AFMD, NAS:ZFGN, NAS:GEMP, NAS:CBAY, NAS:ORMP, NAS:SBPH, NAS:MNKD, NAS:CDTX, NAS:ADVM, OTCPK:INNMF, AMEX:RNN, NAS:SRNE, OTCPK:CTIX, OTCPK:VNLPY, AMEX:PLX, NAS:PRQR, NAS:ARWR, AMEX:PFNX, NAS:CBMG » details
Traded in other countries:9EY.Germany,
Headquarter Location:USA
Endocyte Inc is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.

Top Ranked Articles about Endocyte Inc

Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update
Endocyte Announces First Quarter 2017 Earnings Conference Call
Endocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects Resulting from CAR T-Cell Treatment
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2017

--Presentations to include late-breaker highlighting Endocyte’s next generation CAR T-cell therapeutic platform—

WEST LAFAYETTE, Ind., March 27, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that eight posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2017 to be held in Washington, DC, April 1 - 5, 2017.
Key presentations during the meeting include a late-breaking poster presentation of new research from investigators and faculty at the Purdue University Center for Drug Discovery on the application of Endocyte's SMDC technology in a chimeric antigen receptor (CAR) therapy setting. Additionally, the company will present several posters with preclinical data relating to Endocyte’s SMDC technology, including developments in combination therapies and novel proPBD warheads. The presentation materials will be available on Endocyte’s website following presentation at the conference. Presentations are as follows: Abstract #:  2057Title:  Evaluation of anti-tumor efficacy of EC1456 in low-passage and pre-treated patient-derived xenograft models of triple-negative breast cancerWhen:  Monday, April 3, 1 p.m. – 5 p.m. CDTSession Title:  Drug Resistance: Other TopicsLocation:  Halls A-C, Poster Section 3        Abstract #:  2133Title:  Pre-clinical studies of EC2629, a highly potent FR targeted DNA crosslinking agentWhen:  Monday, April 3, 1 p.m. – 5 p.m. CDTSession Title:  New Targets 2Location:  Halls A-C, Poster Section 6        Abstract #:  LB-187Title:  New methods for controlling CAR T-cell mediated cytokine stormsWhen:  Tuesday, April 4, 8 a.m. – 12 p.m. CDTSession Title:  Late-Breaking Research: ImmunologyLocation:  Poster Section 35        Abstract #:  3670Title:  Treatment of epithelial ovarian cancer with folate receptor (α/β) targeted chemotherapy is enhanced by CTLA-4 blockage: Learning from animal modelsWhen:  Tuesday, April 4, 8 a.m.  – 12 p.m. CDTSession Title:  Dendritic Cells as Critical Immune TargetsLocation:  Halls A-C, Poster Section 27        Abstract #:  3228Title:  Development and characterization of in vitro assays to detect and quantitate tubulysin B hydrazide in biological samplesWhen:  Tuesday, April 4, 8 a.m. – 12 p.m. CDTSession Title:  Novel Molecular Targets 2Location:  Halls A-C, Poster Section 8        Abstract #:  4017Title:  Development and application of an immunohistochemistry-based assay for evaluating functional and accessible folate receptor expression in vivoWhen:  Tuesday, April 4, 1 p.m. – 5 p.m. CDTSession Title:  Assay TechnologyLocation:  Halls A-C, Poster Section 1        Abstract #:  4574Title:  Combinatorial strategies of folate receptor-targeted chemotherapy guided by improved understanding of tumor microenvironment and immunomodulationWhen:  Tuesday, April 4, 1 p.m. – 5 p.m. CDTSession Title:  Clinical Immunotherapy, Viruses, and bacteriaLocation:  Halls A-C, Poster Section 25        Abstract #:  5147Title:  Novel warheads for targeted therapies of cancer: The concept and design of proPBDsWhen:  Wednesday, April 5, 8 a.m. – 12 p.m. CDTSession Title:  Novel Drug Delivery TechnologyLocation:  Halls A-C, Poster Section 5 About Endocyte's SMDC Bi-Specific Adaptors Endocyte's SMDC bi-specific adaptors represent a novel approach that makes possible the engineering of a single universal CAR T-cell, designed to bind with high affinity to fluorescein isothiocyanate (FITC).  This universal CAR T-cell can be specifically directed to cancer cells through the administration of a tumor targeted FITC-containing SMDC, known as a bi-specific adaptor that acts to bridge the universal CAR T-cell with the cancer cells to cause localized T-cell activation.  This approach has been shown pre-clinically to address three key CAR T-cell issues by: (i) avoiding hyper-activation of CAR T-cells leading to a cytokine storm, (ii) enabling termination of CAR T-cell activity upon eradication of the tumor, and (iii) potentially enabling elimination of all cancer cells in heterogeneous solid tumors.  In March 2017, Endocyte entered into a research collaboration with Seattle Children's Research Institute and Dr. Michael Jensen for the development of Endocyte's SMDC platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting through the use of Endocyte's proprietary SMDC bi-specific adaptor molecules. About Endocyte Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies.  The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]

Read more...
Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update

Conference Call Today at 8:30 a.m. EST

WEST LAFAYETTE, Ind., March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the fourth quarter ending December 31, 2016, and provided a clinical and business update.
“We are pleased to report progress on several aspects of the business during the last several weeks,” commented Mike Sherman, president and CEO at Endocyte. “The separately announced collaboration with Seattle Children’s Research Institute and Dr. Michael Jensen, an innovator and thought leader in the field of chimeric antigen receptor T-cell (CAR T-cell) immunotherapies, is an indication of the promise of our technology and a reflection of our commitment to establishing partnerships intended to bring early stage programs to the clinic more rapidly and drive more value from our pipeline. Mike Andriole joining us as chief financial officer also adds significant experience and capacity to pursue value driving partnerships going forward.” “We also anticipate receiving additional clinical data on our lead assets, EC1169 and EC1456, during 2017 as we advance two additional agents toward the clinic,” continued Mr. Sherman. EC1169 (PSMA-tubulysin) Program Outline Currently enrolling patients in the expansion phase of the EC1169 trial in up to 50 second-line chemotherapy and up to 50 taxane-naïve metastatic castrate-resistant prostate cancer (mCRPC) patients at a maximum clinical once per week dose of 6.5 mg/m2Patients are scanned with Endocyte’s proprietary imaging agent, EC0652, to identify the presence of disease that expresses prostate-specific membrane antigen (PSMA)Primary endpoint of this expansion phase is radiographic progression-free survival (rPFS), measured at 5 months for taxane-naïve mCRPC patients and at 3 months for second-line chemotherapy patientsSecondary endpoints which will provide earlier insight into drug activity include overall response rates as measured by response evaluation criteria in solid tumors (RECIST) 1.1 and prostate-specific antigen (PSA)Enrollment is not limited based on the results of the scan with EC0652 but primary endpoints of the trial are to be assessed in PSMA-positive patients EC1456 (Folate-tubulysin) Program Outline Currently enrolling expansion cohort of up to 40 folate-receptor (FR) positive non-small cell lung cancer (NSCLC) patients, as determined by an etarfolatide scan, to receive the maximum clinical twice per week dose of 6.0 mg/m2  Patients included in this expansion phase of the trial will have received first-line chemotherapy and may have also been treated with anti-PD-1 therapyExploring a more frequent dosing schedule, four times per week, in indications that are typically FR-positive, such as ovarian and endometrial cancersAlso conducting an ovarian cancer surgical study to assess various attributes of the drug release within targeted tumors Upcoming Expected Milestones Safety and efficacy updates for both EC1169 and EC1456 ongoing clinical trials expected at the Annual Meeting of the American Society of Clinical Oncology in June, 2017Updated pre-clinical data for CAR T-cell program expected to be presented at a medical conference in the first half of 2017Expect to file Investigational New Drug (IND) application for EC2629 in mid 2017.  EC2629 leverages a proprietary warhead with a dual mechanism of action: targeting both FR cancer cells and tumor associated macrophages (TAMs)Completion of pre-clinical evaluations for CAR T-cell program expected in second half of 2017Initiation of enrollment for EC2629 phase 1 trial expected in second half of 2017Pre-clinical preparatory work on EC2319 in anticipation of potential IND in 2018. EC2319 targets and disables activated macrophages which otherwise produce pro-inflammatory cytokines associated with chronic inflammatory disease Fourth Quarter 2016 Financial Results Endocyte reported a net loss of $11.1 million, or $0.26 per basic and diluted share, for the fourth quarter of 2016, compared to a net loss of $9.8 million, or $0.23 per basic and diluted share for the same period in 2015. Research and development expenses were $8.2 million for the fourth quarter of 2016, compared to $6.4 million for the same period in 2015. The increase was primarily attributable to increases in expenses related to the EC1169 phase 1 trial, including drug manufacturing expenses. General and administrative expenses were $3.1 million for the fourth quarter of 2016, compared to $3.5 million for the same period in 2015. The decrease was primarily attributable to a decrease in compensation expense, which was partially offset by an increase in expenses related to patent and recruiting fees.  Cash, cash equivalents and investments were $138.2 million at December 31, 2016, compared to $146.7 million at September 30, 2016, and $173.6 million at December 31, 2015. Financial Expectations The company anticipates its cash balance at the end of 2017 to be approximately $100 million. About EC1456 and etarfolatide EC1456 is an investigational therapeutic SMDC constructed of a high affinity FR-targeting ligand conjugated through a spacer and bioreleasable linker system to a potent cytotoxic microtubule inhibitor, TubBH. Patient FR-status is determined using the investigational companion imaging agent, etarfolatide. About EC1169 and EC0652 EC1169 is an investigational therapeutic SMDC constructed of a high affinity prostate specific membrane antigen (PSMA)-targeting ligand conjugated through a bioreleasable linker system to a potent microtubule inhibitor, tubulysin B hydrazide (TubBH). Patient PSMA-status is determined using the investigational companion imaging agent, EC0652. Conference Call Endocyte management will host a conference call today at 8:30 a.m. EST. U.S. and Canadian participants:   (877) 845-0711International:   (760) 298-5081                    
A live, listen-only webcast of the conference call may also be accessed by visiting the Investors & News section of the Endocyte website, www.endocyte.com. The webcast will be recorded and available on the company's website for 90 days following the call. Website Information

Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section.  Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD.  Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts.  The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document. About Endocyte Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com. Forward Looking Statements Certain of the statements made in this press release are forward looking, such as those, among others, relating to future spending, future cash balances, the successful completion of current and future clinical trials, the enrollment period for, and availability and reporting, of data from ongoing and future clinical trials, and the company's future development plans including those relating to the completion of pre-clinical development in preparation for possible future clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company may experience delays in the completion of its clinical trials (whether caused by competition, adverse events, patient enrollment rates, shortage of clinical trial materials, regulatory issues or other factors); risks that data from its clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company’s product candidates; risks that early stage pre-clinical data may not be indicative of subsequent data when expanded to additional pre-clinical models or to subsequent clinical data; risks that evolving competitive activity and intellectual property landscape may impair the company's ability to capture value for the technology; risks that expectations and estimates turn out to be incorrect, including estimates of the potential markets for the company’s product candidates, estimates of the capacity of manufacturing and other facilities required to support its product candidates, projected cash needs, and expected future revenues, operations, expenditures and cash position. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Endocyte, Inc. Statements of Operations (dollars in thousands, except per share amounts) (unaudited)     For the Three Months
Ended December 31,  For the Twelve Months
Ended December 31,   2015   2016   2015   2016              Collaboration revenue $12   $12   $70   $70 Costs and expenses:                Research and development  6,386    8,188    26,309    27,492 General and administrative  3,527    3,096    15,734    17,298 Total costs and expenses  9,913    11,284    42,043    44,790 Loss from operations  (9,901)   (11,272)   (41,973)   (44,720)                 Interest income, net  162    232    652    861 Other income (expense), net  (55)   (25)   51    (29)Net loss $(9,794)  $(11,065)  $(41,270)  $(43,888)                    Net loss per share - basic and diluted $(0.23)  $(0.26)  $(0.98)  $(1.04)                    Comprehensive loss $(9,897)  $(11,137)  $(41,205)  $(43,849)                    Weighted average number of common shares used in net
loss – basic and diluted per share:  41,984,763    42,289,453    41,939,504    42,210,643 
Endocyte, Inc. Balance Sheets (in thousands)     As of
December 31,  As of
December 31,   2015  2016      (unaudited) Assets        Cash, cash equivalents and investments $173,600  $138,207 Other assets  4,786   5,287 Total assets $178,386  $143,494          Liabilities and stockholders’ equity        Current liabilities $6,189  $5,562 Deferred revenue and other liabilities, net of current portion  851   785 Total stockholders’ equity  171,346   137,147 Total liabilities and stockholders’ equity $178,386  $143,494 
Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]

Read more...
Endocyte and Seattle Children’s Research Institute to Collaborate on Endocyte’s Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules for CAR T-cell Therapies

Collaboration pairs leading SMDC technology with recognized CAR T-cell research expert Plans to develop next generation CAR T-cell therapeutic platform with potential for improved safety and efficacy in solid tumor indications WEST LAFAYETTE, Ind., March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced their plan to collaborate with Seattle Children’s Research Institute and Dr. Michael Jensen for the development of Endocyte’s SMDC platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting through the use of Endocyte’s proprietary SMDC bi-specific adaptor molecules. The aim of the research collaboration is to join Endocyte’s SMDC bi-specific adaptor technology with the CAR T-cell immunotherapy research efforts at the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute, to move these potentially enabling technologies more quickly to patients in the clinic. Dr. Jensen, a recognized leader in the field of CAR T-cell research, is the director of Ben Towne Center for Childhood Cancer Research and the Janet and Jim Sinegal Endowed Chair in Pediatric Solid Tumor Research at Seattle Children’s Research Institute, and a professor of hematology-oncology at the University of Washington School of Medicine. “This partnership brings together Dr. Jensen’s expertise in the discovery and development of CAR T-cell therapies and Endocyte’s SMDC platform, with the aim of improving the efficacy and safety of CAR T-cell therapies and enabling them in solid tumor indications,” said Mike Sherman, president and CEO of Endocyte. “Together, Seattle Children’s Research Institute and Endocyte hope to make a meaningful difference in shaping the future of CAR T-cell therapies and offering an important new treatment option to cancer patients.” “This collaborative project with Endocyte represents a next-generation CAR T-cell therapeutic platform with exciting opportunities to target solid tumors,” said Dr. Michael Jensen. “We have been impressed with the potential of Endocyte’s bi-specific adaptor molecules, which enable the engineering of a single universal CAR T-cell that binds with very high affinity, potentially allowing us to address several key challenges of current therapies in this novel area of development.” Research and development activities under the collaboration will be led by Dr. Michael Jensen and Dr. Phil Low, chief scientific officer at Endocyte and professor of chemistry and director of the Center for Drug Discovery at Purdue University. About Endocyte’s SMDC Bi-Specific Adaptors Endocyte’s SMDC bi-specific adaptors represent a novel approach that makes possible the engineering of a single universal CAR T-cell, designed to bind with high affinity to fluorescein isothiocyanate (FITC).  This universal CAR T-cell can be specifically directed to cancer cells through the administration of a tumor targeted FITC-containing SMDC, known as a bi-specific adaptor, that acts to bridge the universal CAR T-cell with the cancer cells to cause localized T-cell activation.  This technology may address or mitigate several challenges of current CAR T-cell therapies, such as i) the inability to control the rate of cytokine release and tumor lysis, ii) the absence of an "off switch" that can terminate cytotoxic activity when tumor eradication is complete, and iii) a requirement to generate a different CAR T-cell for each unique tumor antigen. About Endocyte Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies.  The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com. Forward Looking Statements Certain of the statements made in this press release are forward looking, such as those relating to the company’s development programs and upcoming milestones. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company may experience delays in the completion of its clinical trials (whether caused by competition, adverse events, patient enrollment rates, shortage of clinical trial materials, regulatory issues or other factors); risks that data from its clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company’s product candidates; risks that early stage preclinical data may not be indicative of subsequent data when expanded to additional preclinical models or to subsequent clinical data; risks that evolving competitive activity and intellectual property landscape may impair the company's ability to capture value for the technology; estimates of the potential markets for its product candidates; estimates of the capacity of manufacturing and other facilities required to support its product candidates; projected cash needs; and expected future revenues, operations, expenditures and cash position. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:

Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]

Read more...
Endocyte Announces Fourth Quarter and Full Year 2016 Earnings Conference Call

WEST LAFAYETTE, Ind., March 02, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Friday, March 10th, at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International). The webcast will be recorded and available on the Company’s website for 90 days following the call. About Endocyte Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]

Read more...
Endocyte to Present at the Cowen and Company 37th Annual Health Care Conference

WEST LAFAYETTE, Ind., March 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company’s management team will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8th at  8:00 a.m. EST.  The conference is being held at the Boston Marriott Copley Place.
About Endocyte Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.83
ECYT's PB Ratio is ranked higher than
95% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ECYT: 0.83 )
Ranked among companies with meaningful PB Ratio only.
ECYT' s PB Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.28 Max: 11.65
Current: 0.83
0.63
11.65
EV-to-EBIT 0.45
ECYT's EV-to-EBIT is ranked higher than
91% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ECYT: 0.45 )
Ranked among companies with meaningful EV-to-EBIT only.
ECYT' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.6  Med: -1.25 Max: 30.6
Current: 0.45
-50.6
30.6
EV-to-EBITDA 0.46
ECYT's EV-to-EBITDA is ranked higher than
92% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ECYT: 0.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
ECYT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.6  Med: -1.25 Max: 26.1
Current: 0.46
-57.6
26.1
Current Ratio 26.32
ECYT's Current Ratio is ranked higher than
95% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ECYT: 26.32 )
Ranked among companies with meaningful Current Ratio only.
ECYT' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 10.09 Max: 38
Current: 26.32
1.26
38
Quick Ratio 26.32
ECYT's Quick Ratio is ranked higher than
95% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ECYT: 26.32 )
Ranked among companies with meaningful Quick Ratio only.
ECYT' s Quick Ratio Range Over the Past 10 Years
Min: 1.26  Med: 10.09 Max: 38
Current: 26.32
1.26
38
Days Sales Outstanding 25.35
ECYT's Days Sales Outstanding is ranked lower than
95% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ECYT: 25.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
ECYT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.66  Med: 46.93 Max: 286.79
Current: 25.35
3.66
286.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.40
ECYT's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ECYT: -5.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ECYT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -240.4  Med: -5.35 Max: 0
Current: -5.4
-240.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.88
ECYT's Price-to-Net-Cash is ranked higher than
98% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ECYT: 0.88 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ECYT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 2.43 Max: 32.02
Current: 0.88
0
32.02
Price-to-Net-Current-Asset-Value 0.87
ECYT's Price-to-Net-Current-Asset-Value is ranked higher than
98% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ECYT: 0.87 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ECYT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 2.32 Max: 17.28
Current: 0.87
0
17.28
Price-to-Tangible-Book 0.85
ECYT's Price-to-Tangible-Book is ranked higher than
96% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ECYT: 0.85 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ECYT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.79  Med: 1.53 Max: 9.84
Current: 0.85
0.79
9.84
Price-to-Median-PS-Value 126.00
ECYT's Price-to-Median-PS-Value is ranked lower than
99% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ECYT: 126.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ECYT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.75 Max: 229
Current: 126
0
229
Earnings Yield (Greenblatt) % 226.11
ECYT's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ECYT: 226.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ECYT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.3  Med: 141.8 Max: 2545.1
Current: 226.11
3.3
2545.1

More Statistics

Revenue (TTM) (Mil) $0.07
EPS (TTM) $ -1.07
Beta1.24
Short Percentage of Float4.90%
52-Week Range $1.98 - 4.15
Shares Outstanding (Mil)42.47

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.28 -1.31
EPS without NRI ($) -1.28 -1.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ECYT

Headlines

Articles On GuruFocus.com
Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update May 10 2017 
Endocyte Announces First Quarter 2017 Earnings Conference Call May 03 2017 
Screening for Net-Net Stocks in an Overvalued Market Apr 12 2017 
Endocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects Resulti Apr 05 2017 
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2 Mar 27 2017 
Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeli Mar 10 2017 
Endocyte and Seattle Children’s Research Institute to Collaborate on Endocyte’s Small Mole Mar 10 2017 
Endocyte Announces Fourth Quarter and Full Year 2016 Earnings Conference Call Mar 02 2017 
Endocyte to Present at the Cowen and Company 37th Annual Health Care Conference Mar 01 2017 
Merck: Ready to Rise on New Drugs Apr 18 2012 

More From Other Websites
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates May 18 2017
Edited Transcript of ECYT earnings conference call or presentation 10-May-17 12:30pm GMT May 15 2017
Today's Research Reports on Stocks to Watch: Globalstar and Endocyte May 15 2017
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1 May 11 2017
Endocyte reports 1Q loss May 10 2017
Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update May 10 2017
Investor Network: Endocyte, Inc. to Host Earnings Call May 10 2017
Endocyte Announces First Quarter 2017 Earnings Conference Call May 03 2017
What to Expect from Endocyte (ECYT) Stock for Q1 Earnings? May 01 2017
Screening for Net-Net Stocks in an Overvalued Market Apr 12 2017
Endocyte (ECYT) Up 3.5% Since Earnings Report: Can It Continue? Apr 10 2017
Endocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects... Apr 05 2017
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting... Mar 27 2017
Endocyte, Inc. :ECYT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
5 Cheap Breakout Stocks for Superb Returns Mar 16 2017
Endocyte, Inc. :ECYT-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4 Mar 14 2017
Endocyte (ECYT) Shares March Higher, Can It Continue? Mar 14 2017
Edited Transcript of ECYT earnings conference call or presentation 10-Mar-17 1:30pm GMT Mar 12 2017
Endocyte (ECYT) Reports a Wider Q4 Loss Mar 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat